Charles River Associates’ Post

New publication out in MSJ! There are many treatment options for #multiplesclerosis, although, unfortunately, none are curative. Together with Erasmus MC - MS Center ErasMS we investigated if using high efficacy (but also high cost) therapies earlier would be cost-effective. This is relevant as using more costly, but also more effective therapies earlier in the treatment pathway is often not considered due to cost considerations in many countries. We learn three things: One: Certain 'early use of highly effective' therapy treatment-sequences are equally cost-effective to 'step-up' treatment sequences, with larger health gains, but also bearing a risk of overspending. Biosimilars would reduce this risk and make the strategy much more favourable. Two: when comparing 504 possible escalation treatment sequences, cladribine was observed as by far most cost-effective second line option, although its use in the Netherlands is fairly limited. Third: Earlier use of alemtuzumab (which is not frequently prescribed due to very rare side effects and reduced tolerance of prescribing neurologists and patients to its (manageable) side-effect profile) is very cost-effective and yields large health gains. In practice, however, it is generally considered a last resort. Three lessons that deserve follow-up in clinical practice! with Ide Smets, Simone Huygens Beatrijs Wokke and Joost Smolders https://lnkd.in/eihQiMCP

At IGC PHARMA, we are dedicated to highlighting crucial issues in #Alzheimer's Disease #clinicalresearch, particularly the race and ethnic disparities that impact patient outcomes. Our last article in the science spotlight section, authored by Maria Alejandra Tanagrife, Margarita Venegas Ramírez, and Evelyn Gutiérrez, explores the importance of diversity in #clinicaltrials and the need for inclusive #research practices. The article reveals that despite advances in #Alzheimer’s research, significant race and ethnic disparities remain. Diverse representation in #clinicaltrials is essential for the development of effective #treatments that benefit all populations. The authors emphasize that without addressing these disparities, outcomes will continue to be unequal, affecting the overall effectiveness of #Alzheimer's #treatments. Join us in advocating for a future where #clinicalresearch represents all communities. Discover how we can bridge the gap and ensure #equitable outcomes for everyone. Read the full article here: https://lnkd.in/gK8yCXy8 #AlzheimersDisease #ClinicalResearch #DiversityInResearch #Equity #IGCPharma #MedicalResearch #HealthDisparities #Inclusion #RaceAndEthnicity #Innovation

Break the silence on osteoporosis! This World Osteoporosis Day, let's raise awareness about the importance of bone health. Learn more about clinical trials advancing osteoporosis treatment. Did you know? 1 in 3 women and 1 in 5 men over 50 will experience osteoporotic fractures. Join us in the fight against osteoporosis. Explore clinical trials near you. Acceler8 is passionate about improving osteoporosis care through innovative clinical trials and research. Our team works tirelessly to identify effective therapies and enhance patient outcomes. We're always seeking participants to help advance osteoporosis research. #WorldOsteoporosisDay #OsteoporosisAwareness #ClinicalTrials #Bonehealth #MedicalResearch #HealthyBones #AsiaClinicalTrials #SingaporeClinicalResearch #ChinaClinicalTrials #JapanClinicalTrials #UKMedicalResearch

Osteoporosis is a silent condition that affects millions of women, often going undiagnosed until a fracture occurs. At BrookWell Infusion, we are proud to offer Prolia® and Evenity®, two highly effective treatments that address this serious condition. These therapies are designed to strengthen bones and reduce the risk of fractures. Fractures caused by osteoporosis can have a profound and lasting impact on a woman’s independence, mobility, and well-being. Early diagnosis and proactive treatment are essential to prevent these life-altering events. By prioritizing bone health, we can help women lead stronger, healthier lives. If you or someone you know is at risk of osteoporosis, don’t wait to seek medical advice.

☣ ☣ PUBLIC HEALTH EMERGENCY: Individuals with obesity are often excluded from clinical trials. ☣ ☣ 🙏🏽 THANKS Courtney Southwick, MS - Health Science Writer for your great article in HealthCentral Corporation. 💡 💡 MY TWO CENTS: WHY? 💊 Researchers might be disincentivized to include patients with obesity in their trials because of how their weight and weight-related health complications could affect the intervention 💊 Obesity is associated with over 200 complications, some of which may disqualify someone from participating in clinical trials. 💊 Weight bias, stigma, and discrimination likely play a big role. Even when individuals with obesity are eligible for a clinical trial, they might not be inclined to participate for a variety of reasons related to their disease. THE DANGER 🚨 This is a huge problem. 🚨 It’s challenging for clinicians to treat patients with obesity with certain medications if we don’t know which dose or frequency to prescribe. 🚨 Standard dosage and titration regimens could lead to underdosing or overdosing individuals with obesity. CALL TO ACTION 🙋🏽♀️ Raising awareness in a variety of ways is important. 🙋🏽♀️ Health care providers need to be armed with inclusive research, or knowledge of research limitations, so we can treat patients as effectively and safely as possible. 🙋🏽♀️ And patients need to be aware of these research limitations so they can advocate for themselves when medications do not seem to be working or when they develop potential side effects. THANK YOU TO ALL OF THE SMART PEOPLE WORKING ON THIS PROBLEM 🌟 Ted Kyle 🌟 Barbara Senich 🌟 Christina Chow, PhD 🌟 Sundar Srinivasan 🌟 Brandon Fremd 🌟 Christopher Bruno 📰 READ the full article here: https://lnkd.in/e9YAt_Ua Emerald Lake Safety - Obesity Action Coalition - The Obesity Society Weill Cornell Medicine - Krystle Lopez #obesity - #publichealth - #safety - #medications

On World Multiple Sclerosis Day, we aim to raise awareness of the early signs and symptoms of the disease, while promoting the importance of research and treatment development in the area. For healthcare professionals specialising in managing therapies for individuals with multiple sclerosis, Getz Healthcare offers software solutions from Cortechs.ai. This technology automates the quantification of lesions, supplying quantitative data on brain structure and lesions. To learn more about this technology, visit https://lnkd.in/eCEkNmWg. #mutiplesclerosis #ms #neurodegenerativedisease #healthcare #medicine #australia #newzealand

The final issue of The Patient for 2024 has been published (https://lnkd.in/gjBtR5Vk). In this issue: ·   Carolina Navas Cuerva, PhD, DVM et al. review the role of patient reported outcome instruments to measure treatment satisfaction across the life cycle of a drug therapy. They call for an increased measurement of treatment satisfaction in early and late phase drug development. ·   Eva-Lotta Hinzpeter et al. systematically review stated preference research in osteoporosis. They highlight significant heterogeneity and advocate for tailored treatment approaches ·   Benjamin M Craig et al. highlight a novel method for measuring health state preferences – Kaizen Tasks. They suggest a kaizen task is well suited for large descriptive systems or when targeting populations that are difficult to recruit  ·  In a preference study of neurodevelopment follow-up care Pakhi Sharma et al. found there would be a significant uptake of care when families ideal preferences were accounted for. ·  Loria-Rebolledo et al. report that in a study of preferences for intrapartum care in rural areas women preferred to give birth in locations better able to manage complications. ·   Lidia Engel et al. found that the EQ-HWB needs further development in order to be fit for purpose in residential aged care settings ·   Alex Keenan et al. in a stated preference study found that patients with multiple sclerosis being treated with S1PR modulators preferred treatments with shorter immune system recovery time and fewer interactions with other drugs. ·   Thi Quynh Anh Ho  et al. in a qualitative study regarding engagement of young people with web-based mental health interventions, found de-stigmatising campaigns are needed and that young people should be involved in the co-design of interventions ·      The final article in the issue contains the abstracts presented at the recent 15th meeting of the IAHPR. IAHPR Office.

𝐀𝐬 𝐭𝐡𝐞 𝐠𝐥𝐨𝐛𝐚𝐥 𝐩𝐨𝐩𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐞𝐬 𝐭𝐨 𝐚𝐠𝐞, 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’𝐬 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐢𝐬 𝐞𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐚𝐬 𝐚𝐧 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐢𝐧𝐠𝐥𝐲 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞: By 𝟐𝟎𝟓𝟎, 𝟏𝟗% of 𝐈𝐧𝐝𝐢𝐚’𝐬 population and 𝟐𝟐% of 𝐂𝐡𝐢𝐧𝐚’𝐬 population will be over 𝟔𝟎, significantly increasing the demand for Alzheimer's care. In essence, AI-driven diagnostics and advanced therapeutic solutions are playing a key role in improving early detection and better disease management. Industry leaders like 𝐁𝐢𝐨𝐠𝐞𝐧 and 𝐄𝐥𝐢 𝐋𝐢𝐥𝐥𝐲 are at the forefront, further developing innovative treatments to address the unique needs of the aging population. In this light, our latest blog, ‘𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫'𝐬 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 & 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬’ examines the current advancements and emerging trends in the treatment and diagnosis of Alzheimer's, offering valuable insights into the future of patient care and market growth. Check here: https://lnkd.in/dHVqUJmS 𝐻𝑜𝑤 𝑐𝑎𝑛 ℎ𝑒𝑎𝑙𝑡ℎ𝑐𝑎𝑟𝑒 𝑠𝑦𝑠𝑡𝑒𝑚𝑠 𝑠𝑡𝑎𝑦 𝑎ℎ𝑒𝑎𝑑 𝑖𝑛 𝑚𝑒𝑒𝑡𝑖𝑛𝑔 𝑡ℎ𝑒 𝐴𝑙𝑧ℎ𝑒𝑖𝑚𝑒𝑟’𝑠 𝑐𝑎𝑟𝑒 𝑛𝑒𝑒𝑑𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑓𝑢𝑡𝑢𝑟𝑒? Share your thoughts in the comments—we’d love to hear your perspective! . . . Baxter International Inc. Allergan Biogen Cognoptix #alzheimersdisease #therapeutics #diagnostics #diagnosticdevices #healthcare #therapeuticsolutions #patientcare #globaltrends #inkwoodresearch

🔍 Understanding the Impact of Knee and Hip Osteoarthritis Osteoarthritis (OA) is the most common form of arthritis, affecting millions worldwide, and is especially prevalent in the knee and hip joints. As a chronic degenerative disease, OA significantly impacts the quality of life and mobility of affected individuals, leading to challenges in daily activities and overall health. Key Impacts of Knee and Hip Osteoarthritis: Reduced Mobility Economic Burden Mental Health Effects Increased Disability Moving Forward: As healthcare providers and researchers, our mission must be to innovate and apply effective management strategies that enhance quality of life and reduce the burden of OA. Advances in regenerative medicine, personalized treatment plans, and public health initiatives aimed at prevention and education are crucial in battling the widespread impact of osteoarthritis. 🤝 Let's Connect! Are you working in healthcare, policy, or research related to osteoarthritis? I’d love to connect and discuss how we can collaborate to mitigate the effects of this condition. Together, we can improve outcomes for patients worldwide suffering from knee and hip OA. #OsteoarthritisAwareness #ChronicPainManagement #HealthcareInnovation #JointHealth

Cognitive impairment poses significant challenges for healthcare providers, especially in an aging population. Routine screening can unveil issues like dementia early, but effective tools are crucial. The Mini-Cog and MoCA offer quick assessments, bridging the gap before more extensive evaluations. As healthcare marketers, leveraging this need for early diagnosis and innovative assessment tools can enhance patient outcomes. Let's make cognitive health a priority in our strategies! #HealthcareMarketing #CognitiveHealth